Gordon Fox • February 9, 2022
Mavacamten instead of septal reduction?
Mavacamten inhibits the movement of myosin, a key component of heart muscle. Jeff16, CC BY-SA 4.0 https://creativecommons.org/licenses/by-sa/4.0 , via Wikimedia Commons

Many people first discover they have HCM because blood flow out of their heart is obstructed. Some of these patients eventually need to have their septums reduced physically by surgery ( septal myectomy ) or alcohol septal ablation. Can a drug replace these invasive treatments?

On April 2, 2022 Dr. Milind Y. Desai , a leading HCM researcher and practitioner, will present initial results on mava camten ‘s use in severely obstructed HCM patients. Dr. Desai is Director of the HCM Center at the Cleveland Clinic. Scheduled for the American College of Cardiology meeting in Washington. His talk on “Mavacamten as an alternative to surgical septal myectomy or alcohol ablation in patients with severely symptomatic obstructive hypertrophic cardiomyopathy” will present results from the VALOR-HCM trial.

This will be the first set of results on mavacamten’s use in HCM patients who are obstructed. For further background on mavacamten, see this interview with Dr. Martin S. Maron.

HCMA Blog

Cytokinetics Logo of a green
By Erica Friedman May 14, 2025
Positive clinical trial endpoints for MAPLE-HCM study announced by Cyctokonetics for aficamten in obstructive hypertrophic cardiomyopathy
A Caucasian hand with a pen rests on a clipboard that holds paper with writing.
By Gordon Fox May 14, 2025
In the third of a series about decision-making and risk in HCM, Gordon Fox explains where risk data comes from and how to understand it.
4 diverse people stand under the mathmateical formula 25% = 1 in 4.
By Gordon Fox May 13, 2025
In part three of this series on decision making in HCM, Gordon Fox discusses how medical professionals define risk within a patient population, and what the different kinds of risk mean for a patient.
More Posts